XBiotech Inc

For the period ended Dec 31, 2023. Filed Mar 15, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 15, 2024

XBIT$1.97+3.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

	Year Ended December 31,
	2023	2022
Operating activities
Net loss	$(24,557)	$(32,900)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Depreciation	1,744	2,614
Foreign exchange (gain) loss	(1,893)	2,800
Share-based compensation expense	3,262	5,062
Changes in operating assets and liabilities:
Income tax receivable	473	8,556
Accrued interest receivable	356	(1,216)
Prepaid expenses and other current assets	(160)	334
Accounts payable	91	357
Accrued expenses	1,895	229
Income tax payable	123	155
Deferred tax liability	(59)	(815)
Net cash (used in) provided by operating activities	(18,725)	(14,824)
Investing activities
Purchase of property and equipment	(362)	(585)
Proceeds from maturity (purchases of) interest bearing time deposits	61,859	(63,307)
Net cash provided by (used in) investing activities	61,497	(63,892)
Financing activities
Cash paid in tender offer	(14)	-
Issuance of common stock under stock option plan	5	-
Net cash used in financing activities	(9)	-
Effect of foreign exchange rate on cash and cash equivalents	(46)	(961)
Net change in cash and cash equivalents	42,717	(79,677)
Cash and cash equivalents, beginning of year	157,306	236,983
Cash and cash equivalents, end of year	$200,023	$157,306
Supplemental Information:
Purchases of property and equipment in accounts payable	$19	$18

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.